Berenberg has reduced its valuation for Danish pharmaceutical group Novo Nordisk, citing concerns that the company's upside in the obesity segment may be limited by competitive pressures.
The brokerage points to Eli Lilly's dominant position in obesity therapeutics, which it says could restrict Novo Nordisk's ability to expand its own obesity portfolio and sustain growth in that market.
